98%
921
2 minutes
20
The survival rates for children with cancer have increased appreciably over the last few decades; however, childhood cancer survivors continue to suffer from long-lasting sequelae. Studies have demonstrated that the presence of malnutrition, over- and under-nutrition, at diagnosis or the duration of malnutrition during treatment is associated with increased toxicity, infection, and inferior survival. Dietary habits, along with behavioral and socioeconomic status, are known factors that lead to obesity or undernutrition and can affect the prognosis and quality of life of children with cancer. Unfortunately, the underlying mechanisms responsible for these observations are largely unknown. To address this gap in science, we established the EPICkids cohort study, an initiative of the International Initiative for Pediatrics and Nutrition at Columbia University Irving Medical Center and the International Agency for Research on Cancer of the World Health Organization. Over a 5-year period, children and adolescents with acute lymphoblastic leukemia and brain tumors receiving treatment in Spain, Italy, or Greece will be recruited. Clinical data and biospecimens (blood and stool) will be collected at designated timepoints in therapy. At the same time, several surveys will be administered to collect data on sociodemographics, physical activity, quality of life, food insecurity, and dietary habits. The primary aim of EPICkids is to develop a large informative nutrition biobank and database to investigate the etiologic pathways that connect nutritional status and lifestyle factors with clinical outcomes in children and adolescents with cancer. Secondary aims are to create evidence-based guidelines for European children with cancer in this understudied region and to ultimately improve the quality of life of those children and adolescents. The ClinicalTrials.gov ID for EPICkids study is NCT05375617.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412919 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0319110 | PLOS |
Pediatr Blood Cancer
September 2025
Acute Myeloid Leukemia Sub-Committee, Association of Childhood Leukemia Study (JACLS), Japan.
Background: Relapsed or refractory cases of pediatric acute myeloid leukemia (AML) have poor outcomes despite advancements in chemotherapy and hematopoietic stem cell transplantation (HSCT). While a second HSCT is often a salvage option, its outcomes vary widely, and prognostic factors remain unclear.
Objectives: This study aimed to evaluate outcomes and identify prognostic factors in pediatric patients with AML who underwent multiple HSCTs.
Pediatr Blood Cancer
September 2025
Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia, USA.
Moyamoya syndrome (MMS) is a chronic vasculopathy characterized by progressive stenosis of intracerebral arteries, leading to an increased risk of stroke. Children with Down syndrome (DS) are at an increased risk of co-occurring medical conditions, including MMS and leukemia. We report four patients with the triad of DS, MMS, and acute lymphoblastic leukemia (ALL).
View Article and Find Full Text PDFPediatr Blood Cancer
September 2025
Centre for Reviews and Dissemination, University of York, York, UK.
Acute leukaemias are the commonest cancers in children and young people (CYP). Off-treatment surveillance is assumed to improve relapse detection, but whether this affects subsequent survival and quality of life is unclear. This systematic review searched 13 databases and two trial registries in December 2022.
View Article and Find Full Text PDFPediatr Blood Cancer
September 2025
Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK.
Background: Local control strategies in pediatric oncology are guided by disease-specific considerations. Effective communication of the goals of surgical procedure and associated intraoperative events plays a crucial role in shaping subsequent treatment decisions. However, accurately and comprehensively documenting these findings remains challenging, with considerable variability across different tumor types.
View Article and Find Full Text PDFPharmacoepidemiol Drug Saf
September 2025
TriNetX, LLC, Cambridge, Massachusetts, USA.
Introduction: Many clinical data networks often focus on a single use-case or disease. By contrast, the TriNetX Dataworks-USA Network contains real-world clinical information that can be applied to multiple research questions and use cases. The purpose of this study is to describe the Network's characteristics, as well as its generalizability to the US population, particularly the healthcare-seeking population.
View Article and Find Full Text PDF